Clinical Anesthesia Procedures
Transfusion Therapy - Special Considerations
To view the entire topic, please log in or purchase a subscription.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drugs, procedures, and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and PRIME Journals. Explore these free sample topics:
-- The first section of this topic is shown below --
Hemophilia
Hemophilia A and B are rare, sex-linked diseases affecting males almost exclusively. Hemophilia A is due to an abnormality in factor VIII, while hemophilia B (Christmas disease) is due to a factor IX abnormality. The incidence in the United States is 1:10,000 males for hemophilia A and 1:100,000 males for hemophilia.
- Clinical features. Patients usually present early in childhood with hemarthroses and soft tissue hematomas after minor trauma. Laboratory tests demonstrate a markedly prolonged PTT with normal PT and platelet count.
- Treatment with the appropriate factor (of either recombinant or lyophilized concentrate source) should be coordinated with the patient's hematologist. Hemophilia A is treated with factor VIII to achieve preoperative activity levels of 25% to 100%, depending on the extent of the procedure. Some patients with mild hemophilia A may respond to DDAVP therapy. In an emergency, if factor VIII is unavailable, cryoprecipitate transfusion can provide the deficient factor. Hemophilia B is treated with factor IX to achieve at least 30% to 50% activity before surgery.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Hemophilia
Hemophilia A and B are rare, sex-linked diseases affecting males almost exclusively. Hemophilia A is due to an abnormality in factor VIII, while hemophilia B (Christmas disease) is due to a factor IX abnormality. The incidence in the United States is 1:10,000 males for hemophilia A and 1:100,000 males for hemophilia.
- Clinical features. Patients usually present early in childhood with hemarthroses and soft tissue hematomas after minor trauma. Laboratory tests demonstrate a markedly prolonged PTT with normal PT and platelet count.
- Treatment with the appropriate factor (of either recombinant or lyophilized concentrate source) should be coordinated with the patient's hematologist. Hemophilia A is treated with factor VIII to achieve preoperative activity levels of 25% to 100%, depending on the extent of the procedure. Some patients with mild hemophilia A may respond to DDAVP therapy. In an emergency, if factor VIII is unavailable, cryoprecipitate transfusion can provide the deficient factor. Hemophilia B is treated with factor IX to achieve at least 30% to 50% activity before surgery.
There's more to see -- the rest of this topic is available only to subscribers.
